Shares of some U.S. biotechnology companies including Moderna (MRNA) plunged on Monday after reports that the top vaccine ...

Key Takeaways Moderna and other vaccine stocks fell Monday after the Food and Drug Administration's vaccine chief, Peter ...

A preprint study posted late last week on the server medRxiv reveals that the current Moderna COVID-19 vaccine is 53% ...

Moderna stock dips 10% amid FDA resignation, signaling regulatory risks. Strong cash reserves can't offset competitive and ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 12.5% in the morning session after Peter Marks, the ...

Moderna (MRNA) announced that the Australian Therapeutic Goods Administration has granted approval for mRESVIA, an mRNA respiratory syncytial ...

What’s Up With mRNA Research? A research nurse holds an injection of a BioNTech mRNA cancer immunotherapy for non-small cell ...

Julie Hyman outlines the trending stories of the trading day on Market Minute. Moderna (MRNA) shares are falling after a top ...

Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian ...